mci

CANTAB tests predict change in global functioning in patients with amnestic mild cognitive impairments

CANTAB tests predict functional decline in patients with amnestic mild cognitive impairment

Insights Back to resource centre 25 October 2018 CANTAB tests predict functional decline in patients with amnestic mild cognitive impairment We presented a novel, predictive model of functional decline at CTAD 2018. The model suggests that CANTAB PAL and SWM provide essential screening information when recruiting patients with amnestic mild cognitive impairment into Alzheimer’s disease clinical trials. BackgroundDetecting the progression

CANTAB tests predict functional decline in patients with amnestic mild cognitive impairment Read More »

7 tests for assessing cognition in early Alzheimer’s disease

Insights Back to resource centre 27 April 2018 7 tests for assessing cognition in early Alzheimer’s disease With rising life-expectancy, the number of cases of dementia and related disorders is increasing. In attempts to tackle the pandemic, treatment trials are moving earlier in the disease process. CANTAB offers a battery of tests specially targeted at assessing cognition in early Alzheimer’s

7 tests for assessing cognition in early Alzheimer’s disease Read More »

A solution for improving recruitment into early Alzheimer’s disease clinical trials

Insights Back to resource centre 12 April 2018 A solution for improving recruitment into early Alzheimer’s disease clinical trials Screening patients into early stage Alzheimer’s trials can be costly and time-consuming. Kenton Zavitz, PhD, Director of Clinical Affairs proposes a potential solution for improving recruitment into clinical trials. Key pointsScreening patients into early Alzheimer’s trials can be costly and time-consuming.Screening

A solution for improving recruitment into early Alzheimer’s disease clinical trials Read More »

The challenge of detecting early Alzheimer’s disease for clinical trials

Insights Back to resource centre 9 April 2018 The challenge of detecting early Alzheimer’s disease for clinical trials In this post, Director of Clinical Affairs, Dr Kenton Zavitz, looks at the challenge of recruiting the correct patients into Alzheimer’s disease trials. Key PointsAlzheimer’s disease (AD) is a global healthcare and economic crisis.Despite hundreds of clinical trials of new AD treatments,

The challenge of detecting early Alzheimer’s disease for clinical trials Read More »

Scroll to Top